Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3487
Gene Symbol: IGFBP4
IGFBP4
0.010 Biomarker disease BEFREE We compared circulating levels of: a) proglucagon-derived hormones (glucagon-like peptide [GLP]-1, GLP-2, glicentin, oxyntomodulin, glucagon, major proglucagon fragment [MPGF]), b) follistatins-activins (follistatin-like [FSTL]3, activin B), c) IGF axis (insulin-like growth factor [IGF]-1, total and intact IGF binding protein [IGFBP]-3 and IGFBP-4, and pregnancy associated plasma protein [PAPP]-A) in two studies: a) 18 individuals with early stage NAFLD vs. 14 controls (study 1; early NAFLD study) and in b) 31 individuals with biopsy proven NAFLD (15 with simple steatosis [SS] and 16 with nonalcoholic steatohepatitis [NASH]), vs. 50 controls (24 lean and 26 obese) (study 2). 31690932 2020
Entrez Id: 2932
Gene Symbol: GSK3B
GSK3B
0.010 AlteredExpression disease BEFREE However, euglycemic-6R showed both GH and steatosis despite the highest GSK-3β activity and no molecular evidence of increased lipogenesis or decreased ApoB expression, where mitochondrial dysfunction was highest among the groups. 31234955 2020
Entrez Id: 1356
Gene Symbol: CP
CP
0.010 Biomarker disease BEFREE Multivariate analysis showed that CP, age, high density lipoprotein (HDL) and hemoglobin were independent predictors of HS, and CP, body mass index and HDL were independent predictors of moderate and severe HS. 31076363 2020
Entrez Id: 6446
Gene Symbol: SGK1
SGK1
0.010 GeneticVariation disease BEFREE In addition, SGK1 gain-of-function accelerates the development of hepatic steatosis. 31600722 2020
Entrez Id: 5069
Gene Symbol: PAPPA
PAPPA
0.010 Biomarker disease BEFREE We compared circulating levels of: a) proglucagon-derived hormones (glucagon-like peptide [GLP]-1, GLP-2, glicentin, oxyntomodulin, glucagon, major proglucagon fragment [MPGF]), b) follistatins-activins (follistatin-like [FSTL]3, activin B), c) IGF axis (insulin-like growth factor [IGF]-1, total and intact IGF binding protein [IGFBP]-3 and IGFBP-4, and pregnancy associated plasma protein [PAPP]-A) in two studies: a) 18 individuals with early stage NAFLD vs. 14 controls (study 1; early NAFLD study) and in b) 31 individuals with biopsy proven NAFLD (15 with simple steatosis [SS] and 16 with nonalcoholic steatohepatitis [NASH]), vs. 50 controls (24 lean and 26 obese) (study 2). 31690932 2020
Entrez Id: 885
Gene Symbol: CCK
CCK
0.010 Biomarker disease BEFREE CCK receptor antagonist treatment not only prevented NASH but also reversed hepatic inflammation, fibrosis, and steatosis and normalized hepatic transaminases after NASH was established. 31297627 2020
Entrez Id: 23308
Gene Symbol: ICOSLG
ICOSLG
0.010 Biomarker disease BEFREE We found that in steatohepatitis, γδT cells are recruited to the liver by CCR2, CCR5, and NOD2 signaling and are skewed towards an IL-17A<sup>+</sup> phenotype in an ICOS-ICOSL dependent manner. 31529720 2020
Entrez Id: 7247
Gene Symbol: TSN
TSN
0.010 Biomarker disease BEFREE In addition, translin KO mice display prominent hepatic steatosis that is more severe than that of adiposity-matched WT mice. 30647452 2020
Entrez Id: 64850
Gene Symbol: ETNPPL
ETNPPL
0.010 AlteredExpression disease BEFREE Future studies should focus on inhibition of AGXT2L1 activity with the aim of reverting the steatosis induced by LXR activation. 31783151 2020
Entrez Id: 5604
Gene Symbol: MAP2K1
MAP2K1
0.010 Biomarker disease BEFREE Combined LXR ligand (T0901317) and MEK1/2 inhibitor (U0126) not only reduces atherosclerosis in apoE deficient mice, but also blocks LXR ligand-induced fatty liver and hypertriglyceridemia. 31784089 2020
Entrez Id: 10468
Gene Symbol: FST
FST
0.010 Biomarker disease BEFREE We compared circulating levels of: a) proglucagon-derived hormones (glucagon-like peptide [GLP]-1, GLP-2, glicentin, oxyntomodulin, glucagon, major proglucagon fragment [MPGF]), b) follistatins-activins (follistatin-like [FSTL]3, activin B), c) IGF axis (insulin-like growth factor [IGF]-1, total and intact IGF binding protein [IGFBP]-3 and IGFBP-4, and pregnancy associated plasma protein [PAPP]-A) in two studies: a) 18 individuals with early stage NAFLD vs. 14 controls (study 1; early NAFLD study) and in b) 31 individuals with biopsy proven NAFLD (15 with simple steatosis [SS] and 16 with nonalcoholic steatohepatitis [NASH]), vs. 50 controls (24 lean and 26 obese) (study 2). 31690932 2020
Entrez Id: 25897
Gene Symbol: RNF19A
RNF19A
0.010 Biomarker disease BEFREE Macrophage p38α promotes the progression of steatohepatitis by inducing pro-inflammatory cytokine secretion and M1 polarization. p38 inhibition protects against steatohepatitis. 30914267 2019
Entrez Id: 11326
Gene Symbol: VSIG4
VSIG4
0.010 Biomarker disease BEFREE Finally, transplantation of bone marrow cells from control mice to Vsig4-knockout mice restored the severity of steatosis, inflammation and fibrosis after HFD feeding. 31266632 2019
Entrez Id: 91975
Gene Symbol: ZNF300
ZNF300
0.010 AlteredExpression disease BEFREE In the present study, we observed that ZNF300 expression was markedly decreased in free fatty acid (FFA)-induced fatty liver. 30568000 2019
Entrez Id: 259217
Gene Symbol: HSPA12A
HSPA12A
0.010 Biomarker disease BEFREE In-depth molecular analysis revealed that HSPA12A interacted with the M2 isoform of pyruvate kinase (PKM2) in macrophages and increased its nuclear translocation, thereby promoting M1 polarization and secretion of proinflammatory M1 cytokines; this led, ultimately, to hepatocyte steatosis via paracrine effects. 30455376 2019
Entrez Id: 10850
Gene Symbol: CCL27
CCL27
0.010 AlteredExpression disease BEFREE <b>Results:</b> Analysis of data is accompanied with the significant histopathological changes (steatosis, ballooning and inflammation), increased lipid profile and hepatic enzyme activities (AST, ALT, ALP) plus TBARS as well as decreased antioxidants levels in NASH model. 31010354 2019
Entrez Id: 2919
Gene Symbol: CXCL1
CXCL1
0.010 AlteredExpression disease BEFREE CONCLUSION: Hepatic overexpression of CXCL1 is sufficient to drive steatosis-to-NASH progression in HFD-fed mice through neutrophil-derived reactive oxygen species and activation of stress kinases, which can be reversed by IL-22 treatment via the induction of metallothionein. 31705800 2019
Entrez Id: 11001
Gene Symbol: SLC27A2
SLC27A2
0.010 AlteredExpression disease BEFREE Hcy induced steatosis and elevated the expression of CD36 and FATP2 in HepG2 cells. 30973961 2019
Entrez Id: 6590
Gene Symbol: SLPI
SLPI
0.010 AlteredExpression disease BEFREE <b>Results:</b> Analysis of data is accompanied with the significant histopathological changes (steatosis, ballooning and inflammation), increased lipid profile and hepatic enzyme activities (AST, ALT, ALP) plus TBARS as well as decreased antioxidants levels in NASH model. 31010354 2019
Entrez Id: 140576
Gene Symbol: S100A16
S100A16
0.010 AlteredExpression disease BEFREE Overexpression of S100A16 promotes the deterioration of fatty liver induced by HFD, and low expression of S100A16 can attenuate fatty liver. 31069793 2019
Entrez Id: 947
Gene Symbol: CD34
CD34
0.010 Biomarker disease BEFREE Serum Ang-2 levels were increased in patients with histological NASH compared with patients with simple steatosis and correlated with hepatic CD34 immunoreactivity as a marker of hepatic angiogenesis. 30259536 2019
Entrez Id: 1398
Gene Symbol: CRK
CRK
0.010 Biomarker disease BEFREE Macrophage p38α promotes the progression of steatohepatitis by inducing pro-inflammatory cytokine secretion and M1 polarization. p38 inhibition protects against steatohepatitis. 30914267 2019
Entrez Id: 4925
Gene Symbol: NUCB2
NUCB2
0.010 Biomarker disease BEFREE Fatty liver is believed to be sustained by a higher than normal adipose-derived NEFA flux to the liver. 31097978 2019
Entrez Id: 7295
Gene Symbol: TXN
TXN
0.010 Biomarker disease BEFREE Thioredoxin-1 promotes macrophage reverse cholesterol transport and protects liver from steatosis. 31280865 2019
Entrez Id: 64806
Gene Symbol: IL25
IL25
0.010 Biomarker disease BEFREE IL-25 protects against high-fat diet-induced hepatic steatosis in mice by inducing IL-25 and M2a macrophage production. 30242904 2019